Genmab picked up another kick ass milestone from J&J on daratumumab's Phase II.
Genmab banks $22M from J&J as myeloma drug ticks forward
March 27, 2014 | By Damian Garde
Denmark's Genmab is rolling right along with breakthrough-designated daratumumab for double refractory multiple myeloma, hitting a milestone in Phase II development and triggering a $22 million payout from collaborator Johnson & Johnson ($JNJ). J&J signed a deal worth up to $1.1 billion to get its hands on global rights to the drug, taking an $80 million equity stake in Genmab and handing over a $55 million upfront payment. Daratumumab is a CD38 antibody with potential in leukemia and lymphoma, and the drug picked up the FDA's coveted breakthrough therapy designation for multiple myeloma last year.
Article HERE
on another note...
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
-0.001(12.5%) |
Mkt cap ! $14.40M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.7¢ | 0.7¢ | $43.28K | 6.183M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 237374 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 1732079 | 8 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| PAB (ASX) Chart |